The Tantalus System is designed to sense naturally occurring electrical activity of the stomach in real time and automatically apply electrical stimulation when a person eats.
To be considered for the trial, patients must meet certain inclusion criteria, including a diagnosis of type-2 diabetes (treated with oral medications, only), a body mass index between 28 and 45kg/m2 and an age between 18 and 70 years. New York-Presbyterian/Weill Cornell is one of thirty sites in the US participating in the study, which is funded by MetaCure, the manufacturer of Tantalus.
Gregory Dakin, the study’s co-principal investigator, said: “The primary objective of the current study is to evaluate the safety and efficacy of the Tantalus in treating overweight patients with type-2 diabetes. The device’s impact on weight loss, blood pressure and other clinical and metabolic parameters will also be studied.”